Presenters
Course Details
Hypertension is a common cause of heart failure in the Philippines. In this episode of Hypertension Weekly Practice Webisodes of the Philippine Society of Hypertension,
Dr. Richard Henry Tiongco II (University of the Philippines – Philippine General Hospital) discussed the role of hypertension in the pathophysiology of heart failure and the general principles of hypertension management in patients with heart failure. He was then followed by Dr. Gilbert Vilela (Philippine Heart Center), who shared the role of the renin-angiotensin-aldosterone system and the benefits of angiotensin receptor blockers in the hypertension therapy of patients with heart failure.
About the speakers
Dr. Richard Henry Tiongco II is an Associate Professor 7 at the UP College of Medicine Department of Pharmacology & Toxicology and a Clinical Associate Professor in cardiology at the UP-PGH.
Dr. Gilbert Vilela is President of the Philippine Heart Association, Secretary of the Philippine Society of Hypertension, and the Deputy Executive Director for Education, Training and Research of the Philippine Heart Center.
Estimated time of Completion: 1 hr. 43 mins. 24 sec.
CPD Points: 1.5 Points
PRC Program No: PROG-2022-40189
PSH Webisode Series: Hypertension and Heart Failure Course Outline
- Hypertension and Heart Failure (Dr. Tiongco II)
- Determining the burden of disease of hypertension
- Have an overview of the pathophysiological models of hypertension, and that leading to heart failure
- Present the approach to the diagnostics for hypertension
- Discuss the core GDMT for hypertension and heart failure
- Hypertension is Stage A Heart Failure (Dr. Vilela)
- The Cardiovascular Continuum
- Heart Failure is An Insidious Disease that Starts Before the First Symptoms
- Combined Survival Rates of people with HF Over Time
- GWTG-HF Median Survival by Age Group
- Control of Risk Factors is Essential
- Causes of heart failure, common modes of presentation and specific investigations
- Progression From Hypertension to Heart Failure
- Cardiac Remodeling in HF
- Pathophysiology
- Management of Hypertension through Telmisartan
- Intensive treatment and HF progression: SPRINT
- 2021 ESC Guidelines on HF: Primary prevention
- Overview: Antihypertensive treatment in HF patients
- 2020 ISH Guidelines: Ideal characteristics of drug treatment
- 2020 ISH Guidelines: Core drug treatment strategy
- Telmisartan
- Summary
PC-PH-103112 / October 2023